mhurhangee/ep-ind-claims huggingface dataset:
A product consisting of distilled water or of an aqueous solution having an osmolality not higher than 130% of the blood plasma osmolality for administration on the nasal-paranasal mucous membrane, for use in the therapy and prophylaxis of neurological pathologies of the auditory apparatus, or Alzheimer's disease by means of a stimulation of the endogenous production of inflammatory mediators selected from the group consisting of NGF, neurotrophin-3, neurotrophin-4, serotonin, substance P, heparin, ECF-A, wherein said administration on the nasal-paranasal mucous membrane is carried out by either: in a first case, dispensing an amount of product per second of between 2.0 g/sec and 15 g/sec for a dispensing time of between 2.0 sec and 75 sec; or in a second case, dispensing an amount of product per second of between 1.0 g/sec and 15 g/sec for a dispensing time of between 0.4 sec and 10 sec, with the proviso that the mathematical product of ET and PEL does not go beyond 150 g of dispensed product per each administration, wherein said product is selected from the group consisting of: distilled or bidistilled water, sterile tap water, physiological solution (containing NaCl from 0.9% to 0.01% by weight, with or without the addition of glucose), Ringer solution, Ringer lactate solution, Hartmann solution, sulphur solution (in water or distilled water, with concentration from 0.1 mg to 10 mg of H 2 S per litre), ionized alkaline water (having pH between 8 and 11), deionised water and combinations thereof, wherein said administration on the nasal-paranasal mucous membrane is carried out with a daily frequency of between 1 and 6 times a day in said first case, and with a frequency of between 1 and 10 times a day in said second case. in a first case, dispensing an amount of product per second of between 2.0 g/sec and 15 g/sec for a dispensing time of between 2.0 sec and 75 sec; or in a second case, dispensing an amount of product per second of between 1.0 g/sec and 15 g/sec for a dispensing time of between 0.4 sec and 10 sec, with the proviso that the mathematical product of ET and PEL does not go beyond 150 g of dispensed product per each administration, wherein said product is selected from the group consisting of: distilled or bidistilled water, sterile tap water, physiological solution (containing NaCl from 0.9% to 0.01% by weight, with or without the addition of glucose), Ringer solution, Ringer lactate solution, Hartmann solution, sulphur solution (in water or distilled water, with concentration from 0.1 mg to 10 mg of H 2 S per litre), ionized alkaline water (having pH between 8 and 11), deionised water and combinations thereof, wherein said administration on the nasal-paranasal mucous membrane is carried out with a daily frequency of between 1 and 6 times a day in said first case, and with a frequency of between 1 and 10 times a day in said second case.
Method for charging a traction battery of an electric battery-operated vehicle, in particular of an industrial truck, by means of a battery charging system which has a charger for charging the traction battery, a device for ascertaining the current energy price in the electricity supply network, an electronic control device for controlling the charging process, wherein an electronic electricity meter for detesting and for checking the current energy price in an electricity supply network is provided for the purpose of ascertaining the current energy price and the charger is connected to the electricity supply network of an energy supply company by way of the said electronic electricity meter, wherein the electronic control device is connected to the electronic electricity meter, the said method comprising the following steps: • ascertaining the current energy price in the electricity supply network using the electronic control device width the electronic electricity meter, • performing charging of the traction battery using the electronic control device depending on the current energy price and/or the development of the current energy price in the electricity supply network over time, wherein weather data and/or weather forecasts which have an effect on the quantity of regenerative energy produced are detected and taken into account by the battery charging system, wherein predictions for the energy price, which are taken into account in the charging process of the traction battery, are ascertained by the control device on the basis of the weather data and/or weather forecasts. • ascertaining the current energy price in the electricity supply network using the electronic control device width the electronic electricity meter, • performing charging of the traction battery using the electronic control device depending on the current energy price and/or the development of the current energy price in the electricity supply network over time,
A method for controlling sorting machines comprising a plurality of carriages, each carriage comprising a loading-unloading device which can be selectively activated for loading-unloading an object from the carriage and an electronic unit configured to receive and analyse a digital signal, the method comprising the steps of: - moving the carriage along a sorting direction having a plurality of loading stations and a plurality of unloading stations each comprising respective inductors; - generating through the inductors a magnetic field with a variable frequency modulating the digital signal uniquely associated with an operating mode selected from a plurality of operating modes, the digital signal comprising a bit string; - transmitting, by electromagnetic induction, the digital signal to the electronic unit of the carriage; - receiving the digital signal at the electronic unit and activating the loading-unloading device according to the operating mode uniquely associated with the digital signal received from the electronic unit. - moving the carriage along a sorting direction having a plurality of loading stations and a plurality of unloading stations each comprising respective inductors; - generating through the inductors a magnetic field with a variable frequency modulating the digital signal uniquely associated with an operating mode selected from a plurality of operating modes, the digital signal comprising a bit string; - transmitting, by electromagnetic induction, the digital signal to the electronic unit of the carriage; - receiving the digital signal at the electronic unit and activating the loading-unloading device according to the operating mode uniquely associated with the digital signal received from the electronic unit.
A method for applying at least one strip of a pasty product, in particular a binder, on a support, in particular a wall under construction, according to which the pasty product is supplied to a recipient comprising an open face and an operational face, the open face being opposed to the operational face, said operational face being provided with at least one first opening (S1, S1', S1", S7) which extends over a first part of the length of that operational face, said pasty product being spread on the support by having it crossed the or the first opening(s) and thereafter scraped by means of a scraper which is introduced inside the recipient through the open face, which scraper comprises an edge profiled in such a manner as to be provided with at least one second opening, the or the second opening(s) extending each time over a fraction of said profiled edge, and wherein a translation movement which extends over at least said first part is imposed to the scraper while maintaining the recipient in place on the support, characterised in that the recipient is supplied with the pastry product by deposing this pastry product on a second part of the operational face, which second part is offset in the sense of said length with respect of the first part, and in that the pasty product is spread on the support starting from that second part by means of the scraper which is configured in such a manner that the or the second opening(s) are applied in a manner to each time correspond with one of the first openings when the profiled edge of the scraper is face to face with the operational face in a position ready to spread the pasty product, and in that the scraper is positioned on the operational face inside the recipient in such a manner that for the or the stripes to be applied one or some second openings correspond with one or some of the first openings, the pasty product being spread on the support during the translation movement of the scraper, which spreading of the pasty product is followed by a scraping of the spread product in order to form the at least one strip by means of the scraper and remove a surplus of applied product.
Electrolyte composition for depositing a zinc nickel alloy layer comprising a nickel content of 10 to 18 mass-% onto a substrate, wherein the electrolyte composition includes zinc and nickel ions, characterized in that the electrolyte composition comprises amino acetic acid and an acetate of the group consisting of sodium acetate, potassium acetate, ammonium acetate or mixtures thereof in a molar acetate: amino acetic acid ratio of about 0.35 to about 0.91.
A solid cosmetic composition characterized by comprising: a structure agent, the structure agent consisting of a combination of a saturated linear polyethylene and tribehenin; and at least two film forming agents comprising trimethylsiloxysilicate dissolved in cyclomethicone and dimethiconol fluoroalcohol dilinoleic acid, and wherein the composition is further characterized by the absence of mineral, vegetable and animal waxes. a structure agent, the structure agent consisting of a combination of a saturated linear polyethylene and tribehenin; and at least two film forming agents comprising trimethylsiloxysilicate dissolved in cyclomethicone and dimethiconol fluoroalcohol dilinoleic acid, and
The HDM2-p53 interaction inhibitor drug -5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one or a pharmaceutically acceptable salt, solvate, hydrate, complex or co-crystal thereof, for use in the treatment of a haematological tumor, wherein the treatment further comprises adminstration of the BCL2 inhibitor 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(oxan-4yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide [venetoclax], or a pharmaceutically acceptable salt, solvate, hydrate, complex or co-crystal thereof, wherein HDM201 is administered on each of the first 5 days of a 28 days treatment cycle followed by a drug-administration-free period from day 6 until day 28. wherein the treatment further comprises adminstration of the BCL2 inhibitor 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(oxan-4yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide [venetoclax], or a pharmaceutically acceptable salt, solvate, hydrate, complex or co-crystal thereof, wherein HDM201 is administered on each of the first 5 days of a 28 days treatment cycle followed by a drug-administration-free period from day 6 until day 28.
Automatic coffee machine having - a laser beam generated by a laser source, - at least one component in each case having a reflection surface for the laser beam, - a device designed such that it detects and evaluates a travelled distance of the laser beam and identifies and displays an absence or a filling state of at least one component. - a laser beam generated by a laser source, - at least one component in each case having a reflection surface for the laser beam, - a device designed such that it detects and evaluates a travelled distance of the laser beam and identifies and displays an absence or a filling state of at least one component.
A manufacturing method for a header assembly for an implantable intracardiac device, wherein the header assembly comprises at least one tine (3, 103) extending from a base ring (33, 133), wherein the base ring (33, 133) is conically formed, further comprising a header cap (2, 102) and a header base (1, 101), wherein the header cap (2, 102) and the header base (1, 101) each comprise a supporting side surface (43, 53, 143, 153) corresponding to the conical form of the base ring (33, 133), wherein the manufacturing method comprises the following steps: - an assembly step, wherein the conically formed base ring (33, 133) is placed between the header base (1, 101) and the header cap (2, 102) such that the conically formed base ring (33, 133) is located adjacent the supporting header base side surface (53, 153) of the header base (1, 101) and the supporting header cap side surface (43, 143) of the header cap (2, 102), and - a subsequent fixing step, wherein the header cap (2, 102) is permanently fixed to the header base (1, 101) such that the conically formed base ring (33, 133) is located in a base ring groove formed by the supporting header cap side surface (43, 143) and the supporting header base side surface (53, 153). - an assembly step, wherein the conically formed base ring (33, 133) is placed between the header base (1, 101) and the header cap (2, 102) such that the conically formed base ring (33, 133) is located adjacent the supporting header base side surface (53, 153) of the header base (1, 101) and the supporting header cap side surface (43, 143) of the header cap (2, 102), and - a subsequent fixing step, wherein the header cap (2, 102) is permanently fixed to the header base (1, 101) such that the conically formed base ring (33, 133) is located in a base ring groove formed by the supporting header cap side surface (43, 143) and the supporting header base side surface (53, 153).
A method for rapidly screening Trichoderma reesei highly expressing cellulase with high enzyme activity including the steps of introducing the gene expression cassette comprising the elements of cbh1 promoter, red fluorescent protein gene DsRed, cell surface protein anchor signal peptide gene AfMpl and cbh1 terminator into the plasmid to obtain the recombinant expression vector, wherein said DsRed gene has the nucleotide sequence of SEQ ID No.2, and said AfMpl gene has the nucleotide sequence of SEQ ID No.3; transforming the host cell with the recombinant vector constructed in step to obtain the recombinant Trichoderma reesei; introducing a protein secretion pathway related gene or inserting vectors or genes randomly into the recombinant Trichoderma reesei obtained in step 2 to obtain the mutant library of recombinant Trichoderma reesei; screening of the recombinant Trichoderma reesei strongly showing the red fluorescence on its surface by flow cytometry; and determining the cellulase activity of the recombinant Trichoderma reesei obtained in step, to obtain the recombinant Trichoderma reesei with improved cellulase activity. introducing the gene expression cassette comprising the elements of cbh1 promoter, red fluorescent protein gene DsRed, cell surface protein anchor signal peptide gene AfMpl and cbh1 terminator into the plasmid to obtain the recombinant expression vector, wherein said DsRed gene has the nucleotide sequence of SEQ ID No.2, and said AfMpl gene has the nucleotide sequence of SEQ ID No.3; transforming the host cell with the recombinant vector constructed in step to obtain the recombinant Trichoderma reesei; introducing a protein secretion pathway related gene or inserting vectors or genes randomly into the recombinant Trichoderma reesei obtained in step 2 to obtain the mutant library of recombinant Trichoderma reesei; screening of the recombinant Trichoderma reesei strongly showing the red fluorescence on its surface by flow cytometry; and determining the cellulase activity of the recombinant Trichoderma reesei obtained in step, to obtain the recombinant Trichoderma reesei with improved cellulase activity.
An apparatus for providing coupling between at least a first input signal (S in1) with a first signal frequency, and a second input signal (S pi_in2) with a second, different signal frequency, the first input signal (S in1) being a microwave signal, and the second input signal (S pi_in2) being an optical signal, the apparatus comprising: • a first input port; • a second input port; • a first output port; • a second output port; • a first waveguide disposed between the first input port and the first output port; • a second waveguide disposed between the second input port and the second output port, the second waveguide being made of or comprising non-linear material such that a first propagating electromagnetic field generated by microwave photons propagating in the first waveguide and constituting a microwave signal and a second propagating electromagnetic field generated by optical photons propagating in the second waveguide and constituting an optical signal are arranged to overlap and thereby to interact in the non-linear material; • a periodic structure (31, 33) at least within the second waveguide and/or on its surface and/or outside of it for creating at least one photonic band gap; and • a phase-matching arrangement to cause the microwave signal in the first waveguide and the optical signal in the second waveguide to be phase-matched or quasi-phase-matched, wherein the first and second waveguides are non-resonator waveguides configured to allow travelling waves to propagate through the first and second waveguides. • a first input port; • a second input port; • a first output port; • a second output port; • a first waveguide disposed between the first input port and the first output port; • a second waveguide disposed between the second input port and the second output port, the second waveguide being made of or comprising non-linear material such that a first propagating electromagnetic field generated by microwave photons propagating in the first waveguide and constituting a microwave signal and a second propagating electromagnetic field generated by optical photons propagating in the second waveguide and constituting an optical signal are arranged to overlap and thereby to interact in the non-linear material; • a periodic structure (31, 33) at least within the second waveguide and/or on its surface and/or outside of it for creating at least one photonic band gap; and • a phase-matching arrangement to cause the microwave signal in the first waveguide and the optical signal in the second waveguide to be phase-matched or quasi-phase-matched,
A medical instrument (300, 500, 600) comprising: - a high intensity focused ultrasound system comprising an ultrasonic transducer; wherein the ultrasonic transducer comprises multiple transducer elements (400, 402, 404, 406, 408), wherein the high intensity focused ultrasound system is operable for switching on and off the supply of electrical power to each of the multiple transducer elements; - a processor for controlling the medical instrument; - a memory containing machine executable instructions (350, 352, 354, 520, 522, 524); wherein execution of the instructions causes the processor to: - receive (100, 200) a treatment plan specifying a protected zone within a subject; - calculate (102, 208) a set of transducer control parameters using the treatment plan such that an ultrasonic intensity estimate in the protected zone is below a predetermined threshold, wherein the set of transducer control parameters specify the switching of electrical power to each of the multiple transducer elements, characterized in that - the ultrasonic intensity estimate is calculated using an incoherent sum of the ultrasonic pressure generated by each of the multiple transducer elements. - a high intensity focused ultrasound system comprising an ultrasonic transducer; wherein the ultrasonic transducer comprises multiple transducer elements (400, 402, 404, 406, 408), wherein the high intensity focused ultrasound system is operable for switching on and off the supply of electrical power to each of the multiple transducer elements; - a processor for controlling the medical instrument; - a memory containing machine executable instructions (350, 352, 354, 520, 522, 524); wherein execution of the instructions causes the processor to: - receive (100, 200) a treatment plan specifying a protected zone within a subject; - calculate (102, 208) a set of transducer control parameters using the treatment plan such that an ultrasonic intensity estimate in the protected zone is below a predetermined threshold, wherein the set of transducer control parameters specify the switching of electrical power to each of the multiple transducer elements, characterized in that - the ultrasonic intensity estimate is calculated using an incoherent sum of the ultrasonic pressure generated by each of the multiple transducer elements. - receive (100, 200) a treatment plan specifying a protected zone within a subject; - calculate (102, 208) a set of transducer control parameters using the treatment plan such that an ultrasonic intensity estimate in the protected zone is below a predetermined threshold, wherein the set of transducer control parameters specify the switching of electrical power to each of the multiple transducer elements, characterized in that - the ultrasonic intensity estimate is calculated using an incoherent sum of the ultrasonic pressure generated by each of the multiple transducer elements.
A method for processing print products consisting of multiple paper layers, which following the cutting-off from a paper web in a belt line (12, 14, 15) are moved in the direction of a leading open edge, characterized in that the paper layers are releasably connected to one another in the region of the leading edge.
An isolated fusion protein comprising at least one human alpha-1 antitrypsin polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO: 32, and SEQ ID NO: 33, wherein the AAT polypeptide is operably linked to an immunoglobulin Fc polypeptide, wherein the isolated fusion protein exhibits serine protease inhibitory activity and is for use in a method of treating a disease or disorder in a subject selected from AAT deficiency, emphysema, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), allergic asthma, cystic fibrosis, cancers of the lung, ischemia- reperfusion injury, ischemia/reperfusion injury following cardiac transplantation, myocardial infarction, rheumatoid arthritis, septic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, type I and/or type II diabetes, pneumonia, sepsis, graft versus host disease (GVHD), wound healing, Systemic lupus erythematosus, and Multiple sclerosis.